Almost exactly 10 years ago — on June 25, 2015 — I officially registered my first company, Labiotech, in Germany.
I was 24, full of ambition, and convinced that the European biotech industry deserved better media. Back then, most biotech publications were stuck in print, slow to adapt, and fragmented by country and language. It was clear the industry was growing fast, but the way we told its story wasn’t keeping up.
That’s the gap I set out to fill.
Over the next ten years, Labiotech became one of the leading biotech publications in not only Europe but the whole world. We grew from a scrappy blog into a recognized brand, read by thousands of professionals every day. We reported on the rise of CRISPR, the mRNA vaccine boom, and many other incredible innovations. We survived the COVID years, launched our own events, hired amazing journalists, and built a company I’m incredibly proud of.
There were highs, lows, and countless lessons learned, but above all, it was a decade filled with amazing people and meaningful experiences.
In late 2021, I sold Labiotech to Inova (now Inpart), a company whose team I trusted to carry the mission forward. I stayed on to support the transition and make sure the soul of Labiotech — delivering high-quality biotech journalism for free — didn’t get lost.
And they’ve done a great job, expanding the reach of Labiotech well beyond its previous limit while keeping its journalism independent and free. The current team of reporters is full of young, talented reporters I was lucky to hire and mentor, and I’m sure they will be in good hands in the future.
But after a full decade, I know it’s time for me to move on.
Not because I’ve lost interest in biotech (quite the opposite), but because I believe biotech media needs to evolve again. And I want to be the one to build what comes next.
That’s why I’m launching something new: Biotech Snap.
Why I’m launching Biotech Snap?
The internet has changed — again. And this time, the shift is deeper than most media companies are willing to admit.
When I launched Labiotech, the media playbook was relatively clear: write great articles, optimize for search, share on social media, and build a loyal audience over time.
The strategy worked.
We leaned into SEO and free, high-quality content, and Google rewarded us. We mastered distribution through Twitter, LinkedIn, and email. Back then, you could win on quality and consistency alone.
But that world is fading. Fast. And this distribution model is breaking.
Let’s start with search. Google traffic — the lifeblood of many media companies — is no longer reliable. According to multiple publishers, organic traffic from Google is down 20–40% year-over-year for many sites. Why? Because Google is increasingly answering questions directly in its AI overview, rephrasing publisher content without giving them a click.
Meanwhile, social media has become chaotic. Twitter/X is a mess. Facebook has become an AI-image nightmare. Among this chaos, LinkedIn managed to become a strong content platform but is also being rapidly flooded by more and more superficial posts and engagement bait.
At the same time, the way people consume content has changed radically.
I’ve spoken with hundreds of people in biotech — investors, founders, marketers, researchers — and they all say the same thing: “I’m subscribed to dozens of newsletters, but I barely open them.”
Why? Two simple reasons:
- They don’t have time.
- The content isn’t enjoyable to read.
Biotech professionals are overwhelmed, not just with content, but with noise. The inbox is flooded with promotional content, unreadable link dumps, and newsletters that feel like chores. Even the good ones require too much effort, or a paywall, to sift through.
Meanwhile, attention spans are shorter, not because people have gotten lazy, but because the volume of information has exploded. People are busy, distracted, and trying to stay informed without burning out.
Long reads still matter, and there’s absolutely a need for deep reporting. But it’s no longer the default. Today, content needs to fit into the rhythm of modern work: fast, useful, and easy to absorb on the go.
What’s missing is a format built for how we actually consume information today, not how we did in 2015.
Biotech Snap is my vision of this new format.
What is Biotech Snap?
Biotech Snap is a daily newsletter designed for the way biotech professionals actually consume content today.
It’s built to answer one question: “How can I stay informed about biotech in 5 minutes or less without falling behind?”
Here's how it works:
- One short email per day. Not five. Not a digest of links. One focused, curated briefing.
- No clickbait. No filler. Just the core biotech updates you need to know — funding rounds, IPOs, clinical milestones, M&A activity, policy changes, and standout science.
- Written for skimming. Bullet points, bolded keywords, headlines that work like mental shortcuts. You’ll get the signal, not the noise.
- Readable and useful. It’s not dumbed down, but it’s not trying to win a Pulitzer either. It’s biotech news made practical.
- Actually enjoyable. Just because biotech is serious doesn’t mean reading about it has to feel like reading a regulatory PDF. Biotech Snap will have personality, voice, energy, and a sense of rhythm.
Most biotech media today is optimized for clicks, SEO, or ad impressions. Biotech Snap is optimized for you, the reader. For your time, your attention span, and your workflow.
It’s not trying to replace deep reporting. It’s not anti-journalism.
It’s a trusted, fast, high-signal summary of what’s going on in biotech, delivered every morning, without the friction.
You don’t need to scan five newsletters or check three news sites. You just need to open one email.
That’s the vision.
Start your day with Biotech Snap. Stay sharp, save time, and spend your energy where it matters most — whether that’s closing a deal, designing a drug, pitching a startup, or publishing your next big paper.
Want to try it?
👉 Sign up here and get your first edition tomorrow morning.
